Pfizer tests experimental drug to slow stomach emptying in obesity

NCT ID NCT07508241

Ongoing Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This early-stage study tests an experimental drug called PF-08653944 in 20 overweight or obese adults. Researchers want to see how it affects the speed at which the stomach empties food, using a common painkiller as a marker. The main goals are to understand the drug's effects and check for side effects, which could help plan larger future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PF-08653944 (also called MET097)
What this could lead to: If successful, this study could help researchers understand how PF-08653944 affects digestion, potentially guiding future treatments for weight management.
What could go wrong: This is a very early Phase 1 trial with only 20 participants, so results may not apply broadly. The medicine may cause side effects or fail to show meaningful effects on stomach emptying.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG INTERACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG INTERACTION OBESITY OVERWEIGHT OVERWEIGHT AND/OR OBESITY

Contacts and locations

Locations

Pfizer Clinical Research Unit - New Haven

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.